RxDoctor Payments DataLook up a doctor →

Anastasios Manessis, MD

Endocrinology, Diabetes & Metabolism · New York, NYNPI 1467615823

Payments from drug & device makers

$4,437,633in general payments, 2019–2025

Across 3,008 payments — averaging $1475.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.5M
  • Novo Nordisk AS$550K
  • AbbVie$331K
  • Lilly USA, LLC$180K
  • Mannkind Corporation$167K
  • Novo Nordisk$160K
  • plus $569K from 54 others
$125,647in research payments, 2019–2025

Across 9 payments — averaging $13,961 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$126K
  • Novo Nordisk$48

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly43$2,479,128
Novo Nordisk AS835$550,156
AbbVie93$331,475
Lilly USA, LLC395$180,068
Mannkind Corporation197$167,182
Novo Nordisk320$160,374
Sanofi US Services Inc.19$133,843
Ascendis Pharma Endocrinology Inc146$108,057
Medtronic(2 entities)37$85,391
Sanofi-aventis U.S. LLC118$69,716
Boehringer Ingelheim103$52,867
AstraZeneca(2 entities)104$48,242
Senseonics, Incorporated8$13,738
Johnson & Johnson19$12,327
Amgen(2 entities)55$9,528
Boehringer Ingelheim Pharma GmbH & Co.kg2$8,346
Amryt Pharma Holdings Ltd14$6,987
Vistapharm, Inc.5$3,488
Corcept Therapeutics32$3,347
Abbott45$1,601
Pfizer43$1,524
Tandem Diabetes Care, Inc.11$1,087
Xeris Pharmaceuticals, Inc.47$939
Boehringer Ingelheim International GmbH9$767
Antares Pharma, Inc.23$561
Ascensia Diabetes Care US Inc.19$528
Dexcom, Inc.22$465
Insulet Corporation16$459
Amarin Pharma, Inc.29$435
Astellas Pharma US Inc21$430
Intuity Medical Inc13$423
Kowa Pharmaceuticals America, Inc.11$332
Amneal Pharmaceuticals LLC14$304
Merck14$300
Cequr Corporation4$274
Lifescan, Inc.14$240
Bayer8$228
Radius Health, Inc.3$174
Intra-sana Laboratories7$152
Sequel Med Tech, LLC1$135
Currax Pharmaceuticals LLC8$123
Janssen Scientific Affairs, LLC1$123
Novartis7$113
Ultragenyx Pharmaceutical Inc.5$109
Lexicon Pharmaceuticals, Inc.5$107
Recordati_rare_diseases_inc.4$102
BD5$100
IBSA Pharma Inc.5$95
EUSA Pharma (US) LLC3$85
Theratechnologies Inc.2$81
Madrigal Pharmaceuticals2$77
Amphastar Pharmaceuticals, Inc.4$73
Ipsen Biopharmaceuticals, Inc3$70
Endo Pharmaceuticals Inc.3$68
Zealand Pharma US, Inc.3$67
GRT US Holding, Inc.2$62
Treace Medical Concepts, Inc.1$55
Chiesi USA, Inc.2$51
EMD Serono, Inc.2$48
Eisai Inc.2$45

How this compares

$4,437,633 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024
$1,339,149
Medicare patients
1,331
Services billed
26,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →